Nanomedicine & Targeted Delivery

Research |

Polymeric Nanoparticles as Therapeutic Platforms

The nanotechnology as a basic and applied science has uncovered a universe of creative possibilities, impacting almost all aspect of society. Our research attempts to generate advanced therapeutic strategies based on polymeric nanoparticles for the precise delivery of drugs. Since early stages of the preclinical drug development, including the fundamental understanding and interactions of nanoparticles and the life sciences, our group is also focused on the study of pharmacological and toxicological effects of nanoparticles in the physiological and/or pathological conditions. The innovative structure and composition of our nanotherapeutics formulations include the use of novel biomaterials and targeting molecules that support its smart performance and precise organ/tissue delivery. 

Drug Delivery based on Microparticles Technology

The use of polymeric microparticles as controlled release technology provide a broad spectrum of therapeutic applications leading to the sustained release of drugs over long periods of time.

Our goal in this field is to develop innovative microtechnology systems based on novel biodegradable and biocompatible polymers suitable for the encapsulation and controlled release of antibiotics, chemotherapeutics and others molecules via intramuscular, oral and pulmonary delivery.

Novel Biomaterials for Nanotherapeutics

Polymer science is the key of current and future endeavor of drug delivery systems. Several parameter such as loading capacity, stability and the drug release mechanisms depend on the polymeric matrix of formulations. Our aim in this field is 

to develop novel biocompatible materials for the advancement of field of nanotherapeutics.

Funding |

Current Research Support

• Principal Investigator, Fondecyt Regular N° 1201147 (2020-2023).

• Co-Investigator, Fondecyt Regular N° 1181408 (2018-2020).

• Main Research of Basal Grant Nº AFB180001, CEDENNA (Nanobiomedicine, L6), CONICYT (2020 - 2023, III Phase).

• Co-Investigator Nucleus-UNAB 2018 (2018-2020).

• Research Associate of European Union’s Horizon 2020 Research and Innovation Program under the Marie Sklodowsks-Curie Grant Agreement Nº 734801 (2017 - 2021).

• Co-Sponsor of Postdoctoral FONDECYT Funding Nº 3180250 (2018 - 20120).​​